(Q37051414)

17 August 2017

title

Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

17 August 2017

main subject

0 references

0 references

0 references

1 reference

Michael B Sternthal

1

1 reference

17 August 2017

Seamus J Murphy

2

1 reference

17 August 2017

James George

3

1 reference

17 August 2017

Asher Kornbluth

4

1 reference

17 August 2017

Simon Lichtiger

5

1 reference

17 August 2017

Daniel H Present

6

1 reference

17 August 2017

language of work or name

English

0 references

publication date

2 January 2008

1 reference

The American Journal of Gastroenterology

17 August 2017

published in

1 reference

17 August 2017

volume

103

1 reference

17 August 2017

issue

4

1 reference

17 August 2017

page(s)

937-943

1 reference

Cyclosporine in severe ulcerative colitis refractory to steroid therapy

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01718.X

Final report on a placebo-controlled, double-blind, randomized, multicentre trial of cyclosporin treatment in active chronic Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01718.X

Efficacy of cyclosporine in treatment of fistula of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01718.X

Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01718.X

Ciclosporin use in acute ulcerative colitis: a long-term experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01718.X

Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01718.X

Effect of systemic corticosteroid therapy on risk for intra-abdominal or pelvic abscess in non-operated Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01718.X

Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01718.X

Effects of cyclosporine in severe systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01718.X

Prevention and management of the adverse effects associated with immunosuppressive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01718.X

Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01718.X

A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01718.X

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01718.X

Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01718.X

Low-Dose Cyclosporine for the Treatment of Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01718.X

10.1111/J.1572-0241.2007.01718.X

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference